Corbus Pharmaceuticals (CRBP) director receives RSUs and 12,300 stock options

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings director John Kenneth Jenkins received new equity compensation. On May 19, 2026, he was granted 3,800 restricted stock units that will settle in common shares and vest 100% one year after the grant date. He was also granted stock options on 12,300 shares of common stock at an exercise price of $9.15 per share, which likewise vest fully on the one-year anniversary of grant under the company’s 2024 Equity Compensation Plan. Following these awards, his reported beneficial ownership is 8,633 shares of common stock, including 8,600 unvested RSUs subject to their vesting schedules.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Jenkins John Kenneth

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock options (right to buy)	12,300	$0.00	--
Grant/Award	Common Stock, par value $0.0001 per share	3,800	$0.00	--

Holdings After Transaction: Stock options (right to buy) — 12,300 shares (Direct, null); Common Stock, par value $0.0001 per share — 8,633 shares (Direct, null)

Footnotes (1)

1. On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported. The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.

Key Figures

RSU grant: 3,800 RSUs Stock options granted: 12,300 options Option exercise price: $9.15 per share +2 more

5 metrics

RSU grant 3,800 RSUs Granted May 19, 2026; vest 100% after one year

Stock options granted 12,300 options Granted May 19, 2026 under 2024 Equity Compensation Plan

Option exercise price $9.15 per share Exercise price for 12,300 stock options

Shares owned after grants 8,633 shares Common stock beneficially owned following the reported transactions

Unvested RSUs included 8,600 RSUs Unvested RSUs included in reported beneficial ownership

Key Terms

restricted stock units ("RSUs"), vesting schedule, 2024 Equity Compensation Plan

3 terms

restricted stock units ("RSUs") financial

"On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

vesting schedule financial

"This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported"

A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

2024 Equity Compensation Plan financial

"The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jenkins John Kenneth

(Last) (First) (Middle)

C/O CORBUS PHARMACEUTICALS HOLDINGS,INC.

500 RIVER RIDGE DRIVE

(Street)

NORWOOD MASSACHUSETTS 02062

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	05/19/2026		A		3,800(1)	A	$0	8,633(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options (right to buy)	$9.15	05/19/2026		A		12,300		(3)	05/19/2026	Common Stock	12,300	$0	12,300	D

Explanation of Responses:

1. On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

2. This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported.

3. The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.

	/s/ Meghan Houghton, attorney-in-fact for John Jenkins	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Corbus Pharmaceuticals (CRBP) director John Kenneth Jenkins receive in this Form 4?

John Kenneth Jenkins received equity compensation, not an open-market purchase. He was granted 3,800 restricted stock units and stock options on 12,300 shares, both vesting after one year, as part of his role at Corbus Pharmaceuticals.

How many RSUs were granted to John Kenneth Jenkins by Corbus Pharmaceuticals (CRBP)?

He was granted 3,800 restricted stock units on May 19, 2026. These RSUs will be settled in common stock and vest 100% on the one-year anniversary of the grant date, aligning his compensation with future company performance.

What are the key terms of John Kenneth Jenkins’s stock options at Corbus Pharmaceuticals (CRBP)?

He received stock options on 12,300 shares of common stock with a $9.15 exercise price. The options were granted under the 2024 Equity Compensation Plan and will vest fully one year after the grant date, providing potential future upside.

How many Corbus Pharmaceuticals (CRBP) shares does John Kenneth Jenkins beneficially own after these grants?

After the awards, his beneficial ownership is reported at 8,633 common shares. This figure includes 8,600 unvested restricted stock units that remain subject to their individual vesting schedules, reflecting largely unvested, long-term oriented compensation.

Are John Kenneth Jenkins’s new Corbus Pharmaceuticals (CRBP) awards immediate or time-vested?

Both awards are time-vested, not immediately exercisable or settled. The 3,800 RSUs and the 12,300 stock options each vest 100% on the one-year anniversary of the May 19, 2026 grant date, encouraging continued service.